Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mogamulizumab vs Investigator's Choice in Relapsed/Refractory ATL
NCT01626664Phase 2Completed
- Sponsor
- Kyowa Kirin
- Start
- Jun 2012
- Primary completion
- Aug 2015
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of mogamulizumab in adult T-cell leukemia-lymphoma (ATLL) (2 arms), sponsored by Kyowa Kirin. Primary endpoint: Overall Response Rate at 8 weeks. Started Jun 2012; status: completed.
02
Drugs
mogamulizumab
03
Conditions
adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on NCT01626664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01626664.